CRISPR Therapeutics AG (CRSP) Net Equity Issued and Repurchased (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 11 years of Net Equity Issued and Repurchased data on file, last reported at -$722000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased fell 108.48% year-over-year to -$722000.0; the trailing twelve-month figure through Mar 2026 stood at $447.5 million (up 1471.98% YoY), and the FY2025 full-year result was $592.2 million, up 96.94% from the prior year.
• Net Equity Issued and Repurchased retreated to -$722000.0 in Q1 2026, from $305.6 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $305.6 million in Q4 2025 to a low of -$1.0 million in Q2 2024.
• A 5-year average of $71.9 million and a median of $15.0 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased jumped 7145.45% in 2025 and sank 108.48% in 2026, its largest moves.
• Tracing CRSP's Net Equity Issued and Repurchased over 5 years: stood at $970000.0 in 2022, then jumped by 3273.3% to $32.7 million in 2023, then sank by 54.28% to $15.0 million in 2024, then jumped by 1942.92% to $305.6 million in 2025, then sank by 100.24% to -$722000.0 in 2026.
• Business Quant data shows CRSP's Net Equity Issued and Repurchased at -$722000.0 in Q1 2026, $305.6 million in Q4 2025, and $71.3 million in Q3 2025.